BUSINESS● LOW3h ago · Oct 8, 2026, 10:51 AM
Argenx falls after ending late-stage trial for Sjögren's disease therapy
Seeking Alpha Tech · global
Argenx's stock declined following the termination of a late-stage clinical trial for its Sjögren's disease therapy. This event affects the company's pharmaceutical development pipeline and market valuation.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS35m agoBank of Montreal asset management unit launches new Latin America index ETFSeeking Alpha TechBUSINESS36m agoGermany lifts GDP forecast as economy withstands Iran warEuroNews [en]